You are here

Please Comment on Proposed Global Guideline on CLTI

Review guidelines     Submit comments


Comments are due Dec. 3, 2018

The editors of the Global Vascular Guidelines are seeking comments on draft clinical practice guidelines on management of chronic limb-threatening ischemia (CLTI).

Representing the end-stage of peripheral arterial disease, CLTI is a problem of growing prevalence and increased health care costs around the globe. This guideline intentionally seeks to create a new conceptual framework for the treatment of CLTI. It encompasses nomenclature, disease staging and a platform for evidence-based revascularization that will allow for future evolution and quality improvement in the field.

These draft guidelines will be posted until December 3, 2018. Materials are available at

Feedback received during the comment period will be shared with the three co-editors and the Steering Committee.

All are welcome to review these draft guidelines and provide comments, including members of the sponsoring societies, other clinicians who are directly involved in the management of patients with CLTI, referring providers and allied professionals who care for the at-risk population, industry and insurance companies, researchers, patients, caregivers and members of the public.

These guidelines were developed by the GVGTM consortium, launched by the Society for Vascular Surgery, European Society for Vascular Surgery, and the World Federation of Vascular Societies.

Representatives from the three leading societies were asked to serve as co-editors as well as members of the Steering Committee. The Steering Committee recruited a large and diversified writing group, developed the scope and section briefs for the guideline, identified priority questions for commissioned evidence reviews and participated in all stages of writing, consensus debate and editing of the manuscript. To support development of evidence-based recommendations, the Steering Committee commissioned systematic reviews from the U.S. Mayo Clinic Evidence-based Practice Center in Rochester, Minn. All financial support for the GVG was derived directly from the sponsoring societies and without the direct involvement of industry or other external stakeholders.

Oversight from the our feedback is essential to strengthen the content of these guidelines, to ensure relevance in clinical practice and potential for improvements in patient care.

Thank you.

Professor Andrew Bradbury, MBA, MD, FRCS, Birmingham, United Kingdom
Michael S. Conte, MD, San Francisco, California
Professor Philippe Kolh, MD, PhD, Liege, Belgium
GVG Co-Editors societies is limited to budgetary and administrative aspects. More information about the development process appears in the draft manuscript and on the project webpage at